CureVac’s Final Act: Shareholders Seal BioNTech Takeover Deal

The curtain is closing on CureVac’s independent presence in the stock market. Following a conclusive shareholder decision this week, the company’s shares are transitioning from a speculative biotech investment into a straightforward calculation tied to its acquisition by BioNTech. With the market already pricing the transaction as complete, investors face a rapidly closing window to exchange their holdings.

Shareholders Deliver Resounding Approval

The prolonged uncertainty surrounding the Tübingen-based firm’s future has reached its conclusion. During an extraordinary general meeting, investors created definitive momentum by approving the takeover and its associated restructuring with an overwhelming 99.16 percent majority. This vote removes the final significant obstacle for BioNTech to fully integrate CureVac’s mRNA technology platform and oncology research pipeline.

Critical Deadlines Loom for Remaining Investors

For shareholders who have not yet acted, the calendar now holds greater significance than any stock chart. BioNTech’s public share exchange offer is nearing its expiration.
* Immediate Action Required: To ensure a seamless process, investors should tender their shares by the evening of December 2, 2025.
* Formal Expiration: The offer technically concludes on December 3, 2025.

Should investors sell immediately? Or is it worth buying CureVac?

Missing these deadlines carries substantial risk, potentially leaving shareholders in precarious territory. The likely outcomes are a “squeeze-out” procedure or a delisting, either of which would severely restrict the tradability of the shares. Given the exceptionally high approval rate, market observers consider it certain that BioNTech will achieve the necessary quotas to execute these steps.

Stock Performance Now Tethered to BioNTech

The fundamental nature of CureVac’s stock has been transformed. What was once a speculative biotech wager is now a pure arbitrage play. The share price no longer reacts to clinical trial data but is mathematically linked to the performance of BioNTech stock. This relationship is dictated by the fixed exchange ratio of 0.05363 BioNTech shares for each single CureVac share.

Trading at 4.66 euros on Friday, hovering near its 52-week high, the price action sends a clear signal: the market has fully priced in the acquisition and is discounting any remaining deal risks. CureVac’s volatility now simply mirrors the price movements of its future parent company based in Mainz. For the financial markets, this marks the end of CureVac’s chapter as an independent competitor in the mRNA race.